搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
BioSpace
1 小时
Regeneron and Sanofi’s Dupixent Tipped to Dominate COPD Biologics Market
Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into ...
东方财富网
4 小时
医药早参 | 康方生物融资19.42亿,三季报进入密集披露期
10月13日, 康方生物 宣布完成新一轮股票配售,成功融资约19.42亿港元。本次融资金额的70%将用于加速 康方生物 自主研发新药在全球范围内的临床开发。 诺和诺德 以其 减肥药 Wegovy闻名于世,正在利用 AI 创新来简化运营并提高效率。 通过在印度(全球最大的糖尿病药物市场之一)进行战略定位, 诺和诺德 预计将通过提高生产能力来满足日益增长的需求。
MyChesCo on MSN
6 小时
GSK’s AREXVY Vaccine Shows Promising Results Across Three RSV Seasons
GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the efficacy and safety of ...
Becker's Hospital Review
8 小时
New drug can treat common nasal disease: GSK
GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.
BioPharma Dive
13 小时
GSK says antibody drug succeeds in testing for chronic nasal condition
The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.
13 小时
Ask Dr. Chatbot? AI is giving us unsafe health advice, study shows
Artificial intelligence chatbots cannot be relied on to give accurate, safe or even clear advice about medication, according ...
ENDPOINTS NEWS
13 小时
Two GSK trials with long-acting drug in chronic rhinosinusitis hit prima ...
GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this ...
16 小时
How ‘green’ inhalers could evade Biden’s drug pricing legacy
The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce ...
17 小时
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction ...
On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the ...
18 小时
Where is the UK investment summit? Sir Keir Starmer to welcome CEOs to London with King to ...
Investment in the UK will be on the agenda, with speakers from the NHS, Google and numerous insurance companies ...
来自MSN
20 小时
TSMC To Exceed Profits, Plans European Factories; Boeing Cuts 17,000 Jobs; Berkshire Boosts ...
TSMC is planning new factories in Europe focused on AI chips after starting construction on its first plant in Dresden, ...
pharmaphorum
20 小时
GSK asthma hope depemokimab works in second indication
Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈